Our JACC editorial on the RESHAPE-HF2 trial: M-TEER in FMR-Erasing all doubt. RHF2 pts had lower EROA and ↑ LVEDV c/w COAPT (i.e. mostly mod FMR), w/substantially lower rates of mortality and HFH at 2 years. Nonetheless, HFH was markedly reduced and QOL was improved w/MitraClip.
Angina improvement can be predicted before PCI using FFR pullbacks 🔑 @jaccjournals https://t.co/B9urrIUtAv
This might change the field of coronary artery disease
👇 here is why 1/7
🔄From “does TAPSE/PASP affects TEER?” to “does TEER affects TAPSE/PASP?”. Significant ⬆️ from baseline to discharge and trend toward better survival and less HF hospitalizations in “responders”. https://t.co/MC7UR6N7Cn @Ale_MM1988@crimigabriele@MdMontalto
@R_Strobes@BElbarouni@jl35wilsonMD@sgordondoc@CMichaelGibson “MI and repeat revascularization” do not (necessarily) mean “having a heart attack”. Plus, if these secondary endpoints occurred more frequently (over a 10 year period) but did not eventually result in increased mortality then it is not so “inconvenient”
@TCTConference Gametime. 9:45, Emerging Clinical Science & Research: Station 4, MV Repair I. “The Impact of TEER on RV-PA coupling in functional mitral regurgitation”
Big news!
@UNICEF welcomes the endorsement of a new strategy to boost access to the diagnosis, treatment & care of severe noncommunicable diseases by African health ministers at the 72nd session of the @WHO Regional Committee for Africa.
More info: https://t.co/cQ7MR26iOm
“Considering the totality of available evidence, in patients undergoing TAVR with a concomitant indication for OAC, DOACs-based strategy is an effective and safe anticoagulation strategy compared to VKA”
Our recent meta-analysis is now out at https://t.co/Jlrz3tS2IC
@houseofbrackets Il governo è caduto perché diviso su questo ACCESISSIMO testa a testa tra due libri di una lentezza esasperante..quando il Presidente del Consiglio ha sempre tifato Chiedi Alla Polvere